Scadenza: 29 June 2021
Scadenze successive:
20/12/2021 : deadline full-proposal
Topic:
The call aims to coordinate national and regional funding programs for transnational cancer research. The challenge is to promote a transnational collaborative approach between scientific teams to allow the sharing of data and infrastructures and guarantee significant results of higher quality and impact.
In particular, the new call invites to address one of the following two specific objectives:
- Identification and validation of TME subclasses and their contribution to resistance mechanisms: translational research using tumor samples collected from retrospective and / or prospective patient cohorts
- Target TME to improve the efficacy of immunotherapy in human patients.
Ente finanziatore:
Co-funded by the European Commission under Horizon 2020.
For Italy, these are the funding bodies and their respective support criteria:
-Ministry of Health:
-Ministry of University and Research
- Cancer Alliance
-Tuscany region
-Regional Foundation for Biomedical Research
Who can participate:
Companies, Universities, Research Bodies, public and private, as long as the articles of association and / or statute (or equivalent documentation) show that they mainly carry out research activities, Research Bodies (public and private),
Partnership: Mandatory
Status:
Closed
Quota finanziabile:
basic research 70%, applied research 50%, experimental development 25% maximum € 200,000
Topic:
The call aims to coordinate national and regional funding programs for transnational cancer research. The challenge is to promote a transnational collaborative approach between scientific teams to allow the sharing of data and infrastructures and guarantee significant results of higher quality and impact.
In particular, the new call invites to address one of the following two specific objectives:
- Identification and validation of TME subclasses and their contribution to resistance mechanisms: translational research using tumor samples collected from retrospective and / or prospective patient cohorts
- Target TME to improve the efficacy of immunotherapy in human patients.
Who can participate:
Companies, Universities, Research Bodies, public and private, as long as the articles of association and / or statute (or equivalent documentation) show that they mainly carry out research activities, Research Bodies (public and private),
Programme:
Consortium: Required
Status: Open
Total budget:
Funding rate:
basic research 70%, applied research 50%, experimental development 25% maximum € 200,000
Notes:
- A suitability check prior to the submission of the preliminary proposal is mandatory
- A research consortium must not involve more than two research groups from a country and at least one basic or preclinical research team and one clinical team.
